消化道恶性肿瘤TSGF、CA19-9、CA242联合检测的临床评价

目的　探讨用恶性肿瘤特异性生长因子 (TSGF)、糖抗原 19 9(CA19 9)与糖抗原 2 42 (CA2 42 )联合检测对消化道恶性肿瘤的临床评价。方法　采用酶免疫测定 140例消化道肿瘤及 30例正常人血清。结果　以单一指标阳性作为诊断标准CA2 42、CA19 9、TSGF对消化道恶性肿瘤的灵敏度分别为 42 9%、5 5 7%、80 7% ,准确度分别为 5 2 9%、6 2 4%、81 8% ,联合检测结果二项或二项以上阳性作为标准则本组患者的诊断的灵敏度为 84 3% ,准确度为 87 6 %。结论　联合检测血清TSGF、CA19 9与CA2 42对消化道恶性肿瘤的辅助诊断有较高的临床应用价值。

The clinical evaluation of TSGF、CA19-9、CA242 combinedly in detecting malignant tumors in digestive tract

Objective To probe the clinical evaluation of tumor specific growth factor(TSGF), carbohydrate 19-9(CA19-9) and carbohydrate 242(CA242) combinedly in detecting malignant tumors in digestive tract. Methods To determine 140 cases of tumors in digestive tract and the blood sera of 30 normal people with enzyme immunometric assay(EIA). Results The sensitivity rates of using single positive diagnostic indicator of CA242, CA19-9, TSGF to malignant tumors in digestive tract were 42.9%, 55.7% and 80.7%, respectively, and the accuracy rates were 52.9%, 62.4% and 81.8%. In combined detection for two or more positive results, the diagnostic sensitivity rate was 84.3%, and the accuracy rate was 87.6%. Conclusion Detecting TSGF, CA19-9 and CA242 combinedly is of great clinical value to diagnosis malignant tumors in digestive tract.